MARKET

JAZZ

JAZZ

Jazz Pharmaceuticals Plc
NASDAQ
172.72
+2.72
+1.60%
Opening 12:06 01/02 EST
OPEN
169.50
PREV CLOSE
170.00
HIGH
173.95
LOW
169.26
VOLUME
264.08K
TURNOVER
--
52 WEEK HIGH
182.99
52 WEEK LOW
95.49
MARKET CAP
10.50B
P/E (TTM)
-28.4553
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JAZZ last week (1222-1226)?
Weekly Report · 12/29/2025 09:47
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After a Strong Year-to-Date Share Price Rally
Simply Wall St · 12/22/2025 15:09
Weekly Report: what happened at JAZZ last week (1215-1219)?
Weekly Report · 12/22/2025 09:47
EXPLAINER-What will change if the US reclassifies marijuana?
Reuters · 12/17/2025 23:22
Jazz Pharmaceuticals to Present Phase 3 Zanidatamab Trial Results at Investor Webcast
Reuters · 12/17/2025 21:15
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
PR Newswire · 12/17/2025 21:15
Weekly Report: what happened at JAZZ last week (1208-1212)?
Weekly Report · 12/15/2025 09:52
Jazz Pharmaceuticals (JAZZ): Valuation Check After Positive Ziihera and Epidiolex Clinical Updates Boost Investor Interest
Simply Wall St · 12/14/2025 23:22
More
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Webull offers Jazz Pharmaceuticals PLC stock information, including NASDAQ: JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.